KalVista Pharmaceuticals, Inc.
General ticker "KALV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $730.2M (TTM average)
KalVista Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 40.4%.
Estimated limits based on current volatility of 0.2%: low 26.89$, high 26.97$
Factors to consider:
- Total employees count: 150 (+27.1%) as of 2024
- Top business risk factors: Lack of profitability, High R&D costs, Funding dependency, Market competition, Regulatory and compliance
- Current price 22.9% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.14$, 21.92$]
- 2026-12-31 to 2027-12-31 estimated range: [8.83$, 19.63$]
Financial Metrics affecting the KALV estimates:
- Negative: with PPE of -3.9 at the end of fiscal year the price was high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 2.37 > -0.60
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term KALV quotes
Long-term KALV plot with estimates
Financial data
| YTD | 2024-04-30 | 2025-04-30 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $73.62MM |
| Operating Expenses | $140.44MM | $188.00MM | $245.46MM |
| Operating Income | $-140.44MM | $-188.00MM | $-171.84MM |
| Non-Operating Income | $13.80MM | $7.94MM | $0.42MM |
| Interest Expense | $0.00MM | $5.79MM | $19.34MM |
| R&D Expense | $86.17MM | $71.71MM | $55.64MM |
| Income(Loss) | $-126.64MM | $-180.05MM | $-171.42MM |
| Taxes | $0.00MM | $3.39MM | $-7.13MM |
| Net Income(Loss)* | $-126.64MM | $-183.44MM | $-164.29MM |
| Stockholders Equity | $206.58MM | $95.39MM | $-2.71MM |
| Inventory | $0.00MM | $0.00MM | $3.43MM |
| Assets | $235.40MM | $250.77MM | $335.38MM |
| Operating Cash Flow | $-89.23MM | $-152.91MM | $-81.62MM |
| Capital expenditure | $0.44MM | $0.43MM | $1.71MM |
| Investing Cash Flow | $-84.72MM | $91.02MM | $18.68MM |
| Financing Cash Flow | $150.71MM | $159.73MM | $162.64MM |
| Earnings Per Share** | $-3.44 | $-3.69 | $-3.23 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.